Media headlines about Evolent Health (NYSE:EVH) have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Evolent Health earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news stories about the technology company an impact score of 46.5786325466442 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
EVH has been the topic of several recent research reports. Robert W. Baird reaffirmed an “outperform” rating and set a $25.00 price objective (down from $35.00) on shares of Evolent Health in a report on Tuesday, September 26th. They noted that the move was a valuation call. Zacks Investment Research downgraded shares of Evolent Health from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Cowen reaffirmed an “outperform” rating and set a $29.00 price objective (down from $33.00) on shares of Evolent Health in a report on Friday, October 6th. Canaccord Genuity reaffirmed a “buy” rating and set a $32.00 price objective on shares of Evolent Health in a report on Friday, October 6th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $30.00 price objective on shares of Evolent Health in a report on Thursday, November 2nd. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $28.00.
Shares of Evolent Health (NYSE:EVH) opened at $14.20 on Friday. Evolent Health has a fifty-two week low of $10.30 and a fifty-two week high of $27.50. The stock has a market cap of $1,098.17, a PE ratio of -12.57 and a beta of 1.07. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.34 and a quick ratio of 3.34.
Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Thursday, November 2nd. The technology company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.04. Evolent Health had a negative net margin of 15.86% and a negative return on equity of 5.05%. The firm had revenue of $107.90 million for the quarter, compared to the consensus estimate of $104.49 million. During the same period in the prior year, the firm posted ($0.26) earnings per share. The company’s revenue for the quarter was up 79.2% on a year-over-year basis. research analysts predict that Evolent Health will post -0.57 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/21/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-evolent-health-evh-share-price.html.
Evolent Health Company Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.